UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.018

Sortiert nach

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

European journal of cancer (1990), 2016-01, Vol.53, p.75-83

2016

Volltextzugriff (PDF)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

British journal of cancer, 2014-05, Vol.110 (11), p.2756-2764

2014

Volltextzugriff (PDF)

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]

Breast cancer targets and therapy, 2019-05, Vol.11, p.189-190

DA, Yardley

2019

Volltextzugriff (PDF)

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Annals of oncology, 2018-08, Vol.29 (8), p.1763-1770

2018

Volltextzugriff (PDF)

Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

Journal of clinical oncology, 2001-08, Vol.19 (15), p.3500-3505

2001

Volltextzugriff (PDF)

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

Annals of oncology, 2015-09, Vol.26 (9), p.1904-1910

2015

Volltextzugriff (PDF)

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Annals of oncology, 2018-10, Vol.29, p.viii439-viii440

2018

Volltextzugriff (PDF)

Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Journal of clinical oncology, 2001-03, Vol.19 (5), p.1363-1373

2001

Volltextzugriff (PDF)

In pursuit of the prevention of breast cancer

The American journal of the medical sciences, 2000-10, Vol.320 (4), p.263-272

YARDLEY, Denise A

2000

Volltextzugriff (PDF)

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.S1-S1-04

2013

Volltextzugriff (PDF)

Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers

Seminars in radiation oncology, 1999-04, Vol.9 (2 Suppl 1), p.97

1999

Volltextzugriff (PDF)

HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1

Annals of oncology, 2016-10, Vol.27, p.vi99-vi99

2016

Volltextzugriff (PDF)

METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)

Annals of oncology, 2016-10, Vol.27, p.vi97-vi97

2016

Volltextzugriff (PDF)

Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

Annals of oncology, 2015-05, Vol.26, p.iii6-iii6

2015

Volltextzugriff (PDF)

1239TiPMORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Annals of oncology, 2018-10, Vol.29 (suppl_8)

2018

Volltextzugriff (PDF)

Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI)

Journal of clinical oncology, 2011-09, Vol.29 (27_suppl), p.268-268

2011

Volltextzugriff (PDF)

A Phase 1 Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide Alone or Combined with an Aromatase Inhibitor in Women with Advanced Breast Cancer

Annals of oncology, 2014-05, Vol.25, p.i4-i4

2014

Volltextzugriff (PDF)

Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

Breast cancer targets and therapy, 2016-01, Vol.8 (Issue 1), p.73-82

Yardley, Denise A

2016

Volltextzugriff (PDF)

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

Journal of clinical oncology, 2002-10, Vol.20 (20), p.4261-4267

2002

Volltextzugriff (PDF)

Clinical relevance of HER2 expression/activation, as measured in circulating tumor cells by a multiplexed immunoassay, in women with HER2-negative (by FISH) metastatic breast cancer (MBC)

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.TPS125-TPS125

2010

Volltextzugriff (PDF)

Abstract P6-17-36: Consensus and disagreement among experts for treatment of patients with HER2+ early-stage breast cancer suggests unmet need for online decision support tool

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-17-36

2019

Volltextzugriff (PDF)

Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis

Cancer research (Chicago, Ill.), 2019-02, Vol.79 (4_Supplement), p.P6-P6-18-15

2019

Volltextzugriff (PDF)

Taxanes in the elderly patient with metastatic breast cancer

Breast cancer targets and therapy, 2015-01, Vol.7 (default), p.293-301

Yardley, Denise A

2015

Volltextzugriff (PDF)

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

Cancer management and research, 2019-12, Vol.11, p.10427-10433

2019

Volltextzugriff (PDF)

1 – 25 von 1.018

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(870)
Mit Volltextzugriff
(920)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Effect of denosumab versus zoledronic acid in preventing skeletal-related events in patients with bone metastases by baseline characteristics

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER

Taxanes in the elderly patient with metastatic breast cancer [Corrigendum]

nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial

Weekly Docetaxel in the Treatment of Elderly Patients With Advanced Breast Cancer: A Minnie Pearl Cancer Research Network Phase II Trial

Randomized, phase II, placebo-controlled trial of onartuzumab and/or bevacizumab in combination with weekly paclitaxel in patients with metastatic triple-negative breast cancer

MORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Phase I Study of Paclitaxel Given by Seven-Week Continuous Infusion Concurrent With Radiation Therapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck

In pursuit of the prevention of breast cancer

Abstract S1-04: A phase II study of adjuvant paclitaxel (T) and trastuzumab (H) (APT trial) for node-negative, HER2-positive breast cancer (BC)

Seven-week continuous-infusion paclitaxel concurrent with radiation therapy for locally advanced non-small cell lung and head and neck cancers

HERMIONE: A phase 2, randomized, open label trial comparing MM-302 plus trastuzumab with chemotherapy of physician's choice plus trastuzumab, in anthracycline naive HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab and T-DM1

METRIC: A randomized international study of the antibody drug conjugate (ADC) glembatumumab vedotin (GV, CDX-011) in patients (pts) with metastatic gpNMB overexpressing triple-negative breast cancer (TNBC)

Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)

1239TiPMORPHEUS: A phase Ib/II umbrella study platform evaluating the safety and efficacy of multiple cancer immunotherapy (CIT)-based combinations in different tumour types

Results of ENCORE 301, a randomized, phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive (ER+) breast cancer progressing on a nonsteroidal aromatase inhibitor (AI)

A Phase 1 Open-Label Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Enzalutamide Alone or Combined with an Aromatase Inhibitor in Women with Advanced Breast Cancer

Pharmacologic management of bone-related complications and bone metastases in postmenopausal women with hormone receptor-positive breast cancer

Rituximab as First-Line and Maintenance Therapy for Patients With Indolent Non-Hodgkin’s Lymphoma

Clinical relevance of HER2 expression/activation, as measured in circulating tumor cells by a multiplexed immunoassay, in women with HER2-negative (by FISH) metastatic breast cancer (MBC)

Abstract P6-17-36: Consensus and disagreement among experts for treatment of patients with HER2+ early-stage breast cancer suggests unmet need for online decision support tool

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial

Abstract P6-18-15: Ribociclib + endocrine therapy in hormone receptor-positive, HER2-negative advanced breast cancer: A pooled safety analysis

Taxanes in the elderly patient with metastatic breast cancer

First-Line Doublet Chemotherapy for Metastatic Triple-Negative Breast Cancer: Circulating Tumor Cell Analysis of the tnAcity Trial

Suchergebnisse filtern